相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
Zheng Huang et al.
CANCER RESEARCH (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
Zhigang Xie et al.
ONCOTARGET (2013)
Lysine methylation: beyond histones
Xi Zhang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2012)
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4
Xiangao Huang et al.
BLOOD (2012)
Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF-κB Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop
Ping Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
A. Kalff et al.
BLOOD CANCER JOURNAL (2012)
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
Eva Martinez-Garcia et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
Antonia Lopez-Girona et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
Alex J. Kuo et al.
MOLECULAR CELL (2011)
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Huadong Pei et al.
NATURE (2011)
Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
Zhigang Xie et al.
PLOS ONE (2011)
G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53
Jing Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65
Tao Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function
Agda Karina Lucio-Eterovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
MUM1/IRF4 A Review
Gabriela Gualco et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
IRF4: Immunity. Malignancy! Therapy?
Arthur L. Shaffer et al.
CLINICAL CANCER RESEARCH (2009)
The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription
Hee-Bum Kang et al.
FEBS LETTERS (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
The Target of the NSD Family of Histone Lysine Methyltransferases Depends on the Nature of the Substrate
Yan Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome
Keisuke Nimura et al.
NATURE (2009)
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Jotin Marango et al.
BLOOD (2008)
The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
Josh Lauring et al.
BLOOD (2008)
Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion
Zhigang Xie et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity
Ji-Young Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
IRF4 addiction in multiple myeloma
Arthur L. Shaffer et al.
NATURE (2008)
Genetic events in the pathogenesis of multiple myeloma
W. J. Chng et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
Jonathan J. Keats et al.
LEUKEMIA & LYMPHOMA (2006)
Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase
XJ Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
JJ Keats et al.
BLOOD (2005)
Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes
AJ Bannister et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Regulation of p53 activity through lysine methylation
S Chuikov et al.
NATURE (2004)
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis
PS Kho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma
PL Bergsagel et al.
IMMUNOLOGICAL REVIEWS (2003)
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript
M Santra et al.
BLOOD (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
分享论文
